Dorothy Watson

4.3k total citations · 1 hit paper
31 papers, 3.1k citations indexed

About

Dorothy Watson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dorothy Watson has authored 31 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Dorothy Watson's work include Lung Cancer Research Studies (11 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Dorothy Watson is often cited by papers focused on Lung Cancer Research Studies (11 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Lung Cancer Treatments and Mutations (8 papers). Dorothy Watson collaborates with scholars based in United States, Japan and Canada. Dorothy Watson's co-authors include James E. Herndon, Mark R. Green, David J. Sugarbaker, Everett E. Vokes, Gary M. Strauss, David W. Johnstone, Michael A. Maddaus, Elizabeth A. Johnson, Richard L. Schilsky and David H. Harpole and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Dorothy Watson

31 papers receiving 3.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

2008 690 citations Gary M. Strauss, James E. Herndon et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dorothy Watson United States	17	2.3k	1.8k	374	302	298	31	3.1k
Panos Fidias United States	25	1.8k 0.8×	1.7k 1.0×	925 2.5×	170 0.6×	269 0.9×	58	3.0k
Paolo Andrea Zucali Italy	37	2.4k 1.0×	1.1k 0.7×	723 1.9×	201 0.7×	435 1.5×	186	4.1k
Tetsu Shinkai Japan	29	1.8k 0.7×	2.0k 1.2×	782 2.1×	338 1.1×	196 0.7×	146	3.2k
Adolfo Favaretto Italy	31	2.2k 0.9×	1.7k 1.0×	780 2.1×	371 1.2×	231 0.8×	136	3.7k
Matteo Giaj Levra France	18	2.3k 1.0×	1.9k 1.1×	599 1.6×	174 0.6×	236 0.8×	70	3.0k
Russell F. DeVore United States	17	2.4k 1.0×	2.8k 1.6×	1.3k 3.4×	374 1.2×	124 0.4×	29	3.8k
Tomonori Hirashima Japan	31	1.9k 0.8×	1.7k 0.9×	543 1.5×	148 0.5×	147 0.5×	146	2.7k
Shinji Atagi Japan	36	3.3k 1.4×	3.2k 1.8×	819 2.2×	491 1.6×	184 0.6×	182	4.5k
Guy A. Van Hazel Australia	18	913 0.4×	1.9k 1.1×	400 1.1×	120 0.4×	158 0.5×	40	2.4k
Miyako Satouchi Japan	37	3.5k 1.5×	2.8k 1.6×	900 2.4×	344 1.1×	543 1.8×	171	4.8k

Countries citing papers authored by Dorothy Watson

Since Specialization

Citations

This map shows the geographic impact of Dorothy Watson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dorothy Watson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dorothy Watson more than expected).

Fields of papers citing papers by Dorothy Watson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dorothy Watson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dorothy Watson. The network helps show where Dorothy Watson may publish in the future.

Co-authorship network of co-authors of Dorothy Watson

This figure shows the co-authorship network connecting the top 25 collaborators of Dorothy Watson. A scholar is included among the top collaborators of Dorothy Watson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dorothy Watson. Dorothy Watson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Innocenti, Federico, Chen Jiang, Alexander B. Sibley, et al.. (2019). An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenetics and Genomics. 29(6). 123–131. 5 indexed citations

Dressler, Lynn G., Allison M. Deal, Kouros Owzar, et al.. (2015). Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). JNCI Journal of the National Cancer Institute. 107(10). djv188–djv188. 8 indexed citations

Hertz, Daniel L., Kouros Owzar, Susan Halabi, et al.. (2013). A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).. Journal of Clinical Oncology. 31(15_suppl). 11053–11053. 1 indexed citations

Koelwyn, Graeme J., Neil D. Eves, Whitney Hornsby, et al.. (2013). Comparison of performance status with peak oxygen consumption in operable patients with non‐small‐cell lung cancer. Respirology. 19(1). 105–108. 5 indexed citations

Baldwin, R. Michael, Kouros Owzar, Hitoshi Zembutsu, et al.. (2012). A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101. Clinical Cancer Research. 18(18). 5099–5109. 160 indexed citations

Wheeler, Heather E., Eric R. Gamazon, Claudia Wing, et al.. (2012). Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy. Clinical Cancer Research. 19(2). 491–499. 49 indexed citations

Strauss, Gary M., James E. Herndon, Michael A. Maddaus, et al.. (2008). Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. Journal of Clinical Oncology. 26(31). 5043–5051. 690 indexed citations breakdown →

Graziano, Stephen L., James E. Herndon, Mark A. Socinski, et al.. (2008). Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901. Journal of Thoracic Oncology. 3(2). 158–162. 15 indexed citations

Bogart, Jeffrey A., Dorothy Watson, Edward F. McClay, et al.. (2008). Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: Analysis of CALGB phase III trial 9235. Lung Cancer. 62(1). 92–98. 6 indexed citations

10.

Loewen, Gregory, Dorothy Watson, Leslie J. Kohman, et al.. (2007). Preoperative Exercise Vo2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238. Journal of Thoracic Oncology. 2(7). 619–625. 97 indexed citations

11.

Strauss, Gary M., James E. Herndon, Michael A. Maddaus, et al.. (2006). Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. Journal of Clinical Oncology. 24(18_suppl). 7007–7007. 137 indexed citations

12.

Edelman, Martin J., Dorothy Watson, X. Wang, et al.. (2006). Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203. Journal of Clinical Oncology. 24(18_suppl). 7025–7025. 9 indexed citations

13.

Clamon, Gerald H., James E. Herndon, Jeffrey A. Kern, et al.. (2005). Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2. Cancer. 103(8). 1670–1675. 93 indexed citations

14.

Niell, Harvey B., James E. Herndon, Antonius A. Miller, et al.. (2005). Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology. 23(16). 3752–3759. 128 indexed citations

15.

Bogart, Jeffrey A., et al.. (2005). Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002. Journal of Clinical Oncology. 23(16_suppl). 7170–7170. 4 indexed citations

16.

Bogart, Jeffrey A., James E. Herndon, Alan P. Lyss, et al.. (2004). 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. International Journal of Radiation Oncology*Biology*Physics. 59(2). 460–468. 116 indexed citations

17.

Sherman, Carol A., James E. Herndon, Dorothy Watson, & Mark R. Green. (2004). A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer. 45(3). 387–392. 12 indexed citations

18.

Otterson, Gregory A., James E. Herndon, Dorothy Watson, Mark R. Green, & Hedy L. Kindler. (2003). Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer. 44(2). 251–259. 81 indexed citations

19.

Halperin, Edward C., Dorothy Watson, & Stephen L. George. (2001). Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma. Cancer. 91(8). 1444–1450. 54 indexed citations

20.

Morrison, Anne, et al.. (1998). Evaluation and eligibility of HLA‐identical sibling donors for stem cell/bone marrow donation. Transfusion Medicine. 8(3). 215–220. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact